| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_037fe398911aaf8cb7f0a87693172589
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_666d4407f769313bc9d72618c0a9467f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8c9ea0df4ad72093d551e5186620ab1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_187f06fd011a202115f2b1f5482e5f19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_25be3373a77e08ee5b334e667328a217 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| filingDate |
2014-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c6e0d77e50b4d6031e17adc3fadf22d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f9938b99b83c4c56f444feca5a48603
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d195549598b686133c659f8ff4d2af5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8279c49fa9f30c0b2d3eb4c1c9f4a789
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28d201abd77c2644189b7795a362c38a |
| publicationDate |
2019-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
MY-170067-A |
| titleOfInvention |
Method for the treatment of hypercholesterolemia |
| abstract |
Disclosed is a therapeutic management method of hypercholesterolemia in mammals. More specifically, the present invention relates to a method of reducing high levels of circulating cholesterol (hypercholesterolemia) in the blood stream of mammals, said method involving step of administering therapeutically effective amounts of Calebin A to said mammals to bring about the effects of (i) reducing the amount of total blood cholesterol levels; (ii) reducing the concentrations of low density lipoproteins (LDL) and very low density lipoproteins (VLDL); (iii) increasing the concentrations of high density lipoproteins (HDL) and (iv) reducing concentrations of serum triglycerides. |
| priorityDate |
2014-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |